The Hollings Cancer Center Clinical Trials Office (HCC-CTO) provides clinical, regulatory and administrative research services for more than 60 principal investigators. At any one time, the HCC-CTO manages approximately 475 trials - 200 active enrolling trials, 200 closed to accrual trials with patients in follow up, and 75 pending trials in the approval process.
The HCC-CTO has demonstrated success in clinical trial management. Utilizing our local MUSC Institutional Review Board, the average turnaround time for activating a new study from the point of site selection is 105 days (3.5 months). Initiatives are in place to reach an averageactivation period of <90 days. Our annual rate of therapeutic clinical trial enrollment is 12.4 percent of new cancer patients with 21 percent representing minority populations.
The HCC-CTO participates in Phase I, II, and III clinical trials originating from cooperative group participation, selected pharmaceutical trials and investigator-initiated studies. As an NCI-Designated Cancer Center, we have capabilities for conducting phase I trials (see Support Services document below) and managing multicenter studies.
>> Overview of Clinical Research Support Services (PDF)
To learn more about the site capabilities of the Hollings Cancer Center Clinical Trials Office, please contact:
Melanie B. Thomas, MD, MA
Associate Director of Clinical Investigations